Protocol Ledger

NCT03875729 · Phase III · COMPLETED

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

Interventional Phase III clinical trial protocol NCT03875729 sponsored by Sanofi in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-05 Enrollment: 328 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03875729
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)328 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03875729
Protocol FieldVerified Registry Value
NCT IdentifierNCT03875729
Consolidated Lead SponsorSanofi
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment328 participants (ACTUAL)
Registered Start Date2019-04-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI